181 related articles for article (PubMed ID: 31385765)
1. Methotrexate overdose in clinical practice.
Pannu AK
Curr Drug Metab; 2019; 20(9):714-719. PubMed ID: 31385765
[TBL] [Abstract][Full Text] [Related]
2. Acute bone marrow suppression and gastrointestinal toxicity following acute oral methotrexate overdose.
Isoardi KZ; Harris K; Carmichael KE; Dimeski G; Chan BSH; Page CB
Clin Toxicol (Phila); 2018 Dec; 56(12):1204-1206. PubMed ID: 29973099
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
Ghannoum M; Roberts DM; Goldfarb DS; Heldrup J; Anseeuw K; Galvao TF; Nolin TD; Hoffman RS; Lavergne V; Meyers P; Gosselin S; Botnaru T; Mardini K; Wood DM;
Clin J Am Soc Nephrol; 2022 Apr; 17(4):602-622. PubMed ID: 35236714
[TBL] [Abstract][Full Text] [Related]
4. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
5. Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2.
Wormdal OM; Flægstad T; Stokland T
Pediatr Hematol Oncol; 2018; 35(5-6):350-354. PubMed ID: 30672361
[TBL] [Abstract][Full Text] [Related]
6. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
Chan BS; Dawson AH; Buckley NA
Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal leucovorin after intrathecal methotrexate overdose.
Jardine LF; Ingram LC; Bleyer WA
J Pediatr Hematol Oncol; 1996 Aug; 18(3):302-4. PubMed ID: 8689347
[TBL] [Abstract][Full Text] [Related]
8. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.
Prey S; Paul C
Br J Dermatol; 2009 Mar; 160(3):622-8. PubMed ID: 18945303
[TBL] [Abstract][Full Text] [Related]
9. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
[TBL] [Abstract][Full Text] [Related]
10. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.
Cohen IJ
J Pediatr Hematol Oncol; 2004 Mar; 26(3):156-63. PubMed ID: 15125607
[TBL] [Abstract][Full Text] [Related]
11. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
12. Glucarpidase Intervention for Delayed Methotrexate Clearance.
Cavone JL; Yang D; Wang A
Ann Pharmacother; 2014 Jul; 48(7):897-907. PubMed ID: 24742398
[TBL] [Abstract][Full Text] [Related]
13. Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity.
Chan WK; Hui WF
Pediatr Nephrol; 2016 Oct; 31(10):1699-703. PubMed ID: 27335061
[TBL] [Abstract][Full Text] [Related]
14. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.
Ortiz Z; Shea B; Suarez-Almazor ME; Moher D; Wells GA; Tugwell P
J Rheumatol; 1998 Jan; 25(1):36-43. PubMed ID: 9458200
[TBL] [Abstract][Full Text] [Related]
16. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
17. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?
Cansu DÜ; Teke HÜ; Bodakçi E; Korkmaz C
Clin Rheumatol; 2018 Dec; 37(12):3419-3425. PubMed ID: 30056523
[TBL] [Abstract][Full Text] [Related]
18. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications.
Hempel G; Lingg R; Boos J
Cancer Chemother Pharmacol; 2005 Apr; 55(4):347-353. PubMed ID: 15723260
[TBL] [Abstract][Full Text] [Related]
19. Folate supplementation during methotrexate therapy for patients with psoriasis.
Strober BE; Menon K
J Am Acad Dermatol; 2005 Oct; 53(4):652-9. PubMed ID: 16198787
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate with folinic acid rescue.
Bender JF; Grove WR; Fortner CL
Am J Hosp Pharm; 1977 Sep; 34(9):961-5. PubMed ID: 333910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
